As reported on MedCity News, the U.S. Food and Drug Administration (FDA) has introduced a new regulatory pathway that could reshape how treatments are developed for rare diseases. Known as the Plausible Mechanism Framework, the approach allows sponsors to advance highly individualized therapies based on strong biological rationale, rather than relying solely on traditional clinical trial data. For a field long constrained by small patient populations and limited evidence pathways, this marks a meaningful step forward.
The implications are substantial. Rare diseases affect an estimated 30 million individuals in the United States, spanning roughly 10,000 distinct conditions. Yet the vast majority—around 95%—still lack approved treatments. By enabling earlier clinical use of personalized genetic therapies once molecular activity is demonstrated, the FDA has effectively lowered one of the biggest regulatory barriers in this space.
However, while the new framework enables action, it does not address the practical systems needed to deliver therapies to patients. Experts point to five key areas where infrastructure must catch up with regulatory progress.
Moving Beyond Diagnosis to Actionable Assessment
For patients and families, obtaining a diagnosis is often only the first step in a long journey. The more critical question is whether a specific genetic mutation can be treated—and by which modality. Options now range from antisense oligonucleotides (ASOs) and gene replacement to emerging gene-editing approaches and even repurposed drugs.
Evidence suggests that more patients may be eligible for tailored interventions than previously thought. Research from Boston Children’s Hospital indicates that a meaningful portion of rare disease patients could benefit from personalized ASO therapies alone. Yet the information required to make these determinations—spread across genomic databases, scientific literature, and clinical precedents—remains fragmented.
What is lacking is not scientific insight, but a coordinated system to integrate these data and apply them to individual patients. Building such a system represents a solvable operational challenge that could significantly expand access to precision therapies.
Manufacturing Constraints for Individualized Treatments
Even when a treatment strategy is identified, production remains a major bottleneck. Current biopharmaceutical manufacturing systems are optimized for large-scale batches, not single-patient therapies. Fixed costs—particularly for quality control and release testing—remain high regardless of batch size.
Although initial development for an individualized therapy can reach millions of dollars and take considerable time, efficiencies improve as similar cases are treated. Federal initiatives are beginning to address this issue. Programs such as ARPA-H’s THRIVE and GIVE are investing heavily in scalable platforms and distributed manufacturing networks aimed at accelerating production and reducing costs.
The long-term solution is likely to involve shared infrastructure that supports multiple individualized therapies, allowing programs to leverage common processes and reduce duplication. With increased federal support and advancing technology, manufacturing is becoming an engineering problem with clearer pathways to resolution.
Building the Evidence Base for Insurance Coverage
Reimbursement remains another significant barrier. At present, there is no standardized pathway for insurance coverage of individualized therapies. Public programs such as Medicare lack established mechanisms, while private insurers often classify these treatments as experimental, even when supported by regulatory authorization.
Early examples highlight the challenge. The development of Milasen, one of the first customized ASO therapies, relied heavily on philanthropic funding. Without systematic reimbursement models, access remains limited to those able to secure alternative financial support.
Establishing coverage will depend on generating reliable data on outcomes, costs, and delivery processes. Capturing standardized clinical and economic data from the outset of each program is critical. Over time, this information can provide the basis for insurers to evaluate value and develop reimbursement frameworks.
Leveraging AI to Scale Precision Medicine
Many of the current challenges stem from fragmented knowledge rather than lack of capability. Data relevant to therapy design, regulatory processes, and manufacturing already exists across multiple domains—but is not readily integrated.
Artificial intelligence offers a path to unify and operationalize this information. AI tools could match patients with development partners, streamline regulatory documentation, coordinate manufacturing schedules, and standardize outcomes tracking. Importantly, each new case contributes additional data that can make future efforts faster and more efficient.
Rather than requiring breakthroughs in fundamental science, the opportunity lies in applying existing technologies to create repeatable workflows. This shift could transform individualized therapies from isolated successes into scalable solutions.
Expanding Awareness and Access
Finally, ensuring that families are aware of and can access these emerging options is essential. Rare diseases affect a significant portion of the population, yet many patients remain undiagnosed or misdiagnosed for years. The diagnostic process often involves multiple providers and incorrect assessments before a definitive answer is reached.
Genetic counselors—numbering only a few thousand nationwide—are a key touchpoint for these patients. Empowering them with the tools and knowledge needed to guide families toward personalized treatment opportunities could dramatically expand reach.
Addressing this gap is largely a matter of distribution and education. With the right systems in place, more families could learn about and benefit from advances that are already technically feasible.
From Breakthrough Policy to Real-World Impact
The FDA’s Plausible Mechanism Framework represents a pivotal moment in rare disease therapeutics. It acknowledges that traditional clinical trial models are not always appropriate for ultra-rare conditions and opens the door to more flexible, biology-driven approaches.
Yet regulatory progress alone is not enough. Delivering on this promise will require coordinated advances in data integration, manufacturing, reimbursement, technology, and patient access.
The science underpinning individualized genetic therapies is no longer the primary limitation. The remaining challenge is execution—building the systems that can reliably translate innovation into treatment for every patient who might benefit.
